PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

OPTIMAL VALUES OF TESTOSTERONE IN THE COURSE OF THE THERAPY OF ADVANCED PROSTATIC CARCINOMA
Article published in Urologia Polska 1989/42/2.

authors

Jan Szymanowski, Ewa Ko¼mińska, Stefan Zgliczyński
Z Oddzia³u Urologii Szpitala Bielańskiego w Warszawie
Ordynator: dr n. med. J. Szymanowski Z Kliniki Endokrynologii CMKP w Warszawie Kierownik: prof. dr hab. med. S. Zgliczyński

summary

The aim of the work is to evaluate the influence of total testosterone (T) concentration in the blood serum on the stabilization of advanced prostatic ade­noma. The stabilization mean the regression of complaints, lack of local carcinoma progression and preservation of normal activity of phosphates in the blood serum. Concentration T was determined in the blood serum of 45 patients with advanced prostatic carcinoma, among 14 (31.1°/o) with metastasis. The patients were admini­stered phosthrolin and parlodel (orally). The observation lasted 5 years (on the average). Concentration T in the blood serum was 1?4 ng/ml in 22 (48.9%) pa­tients, more than 4 ng/ml in 12 patients (26.7%), less than 1 ng/ml ? in 11 (24.4%) patients. The stabilization was observed in 39 (86.7%) patients whereas worsening in in 6 (13.3%), among them in 2 (4.4% of the total number) in whom the concen­tration was less than 1 ng/ml.
It seems that the stabilization of prostatic carcinoma may be connected with the preservation of T concenrations in the blood serum typical for the age of patients.

references

  1. 1. Fukutani K., Isurugi K., Ishida H., Yokoyama M.: Effects of estrogens on the testosterone levels of peripheral and spermatic vein blood in patients with prostatic cancer. J. Urol., 1979, 122, 5, 624. ? 2. Hickey D., Todd B., Soloway M. 5.: Pre-treatment testosterone levels: significance in androgen deprivation therapy. J. Urol., 1986, 136, 5, 1038. ? 3. Labrie F.: New hormonal therapy for prostatic can­cer: a combined treatment with an LHRH agonist and antiandrogen. J. Clin. Med., 1982, 5, 267. ? 4. Robinson M.R.G., Thomas B.S.: Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Brit. Med. J., 1971, 4, 391. ? 5. Schulze H., Isaacs J., Senge T.: Inability of complete androgen blockade to in­crease survival of patients with advanced prostatic cancer as compared to stan­dard hormonal therapy. J. Urol., 1987, 137, 5, 909. ? 6. Shearer R. J., Hendry W. F? Sommerville I. F., Fergusson J. D.: Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Brit. J. Urol., 1973, 45, 668. ? 7. Szymanow­ski J., Baranowska B., Niewiadomska A., Wysocki M., Kobuszewska-Faryna M., Zgliczyński S.: L'interdependence entre les troubles hormonaux, le stade d'evolution et le degre de malignite du cancer de la glande prostatique (I). J. d'Urol., 1983, 89,
  2. 8, 597. ? 8. Szymanowski J., Baranowska B., Rozbicka G, Jeske W., Zgliczyński S.:
  3. L'interdxpendence entre les troubles hormonaux, le stade d evolution et le degre
  4. de malignite du cancer de la glande prostatique (II). J. d'Urol., 1983, 89, 9, 663. ?
  5. 9. Trachtenberg J.: Optimal testosterone concentration for the treatment of pros­
  6. tatic cancer. J. Urol.. 1985, 133, 5, 888.